Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ CM AXSM (Common Stock) $3.65 - 0.05 (1.35%)
Stock chart for: AXSM.O.  Currently trading at $3.65 with a 52 week high of $12.69 and a 52 week low of $3.55.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference

March 23, 2017NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on April 5, 2017 at 8:40 AM Eastern Time. The conference will be held at The Westin NY Grand Central Hotel in New York... 

Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock

March 21, 2017NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering of 3,743,316 shares of its common stock at a public offering price of $3.74 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses... 

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

March 20, 2017NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Axsome intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offer... 
Axsome Therapeutics

Axsome Therapeutics